x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:20:53

Tamoxifen

OncoPharm ·

2019/07/03

The Foundations in #Oncopharm series returns with the story of a failed contraceptive candidate that became the first (?) targeted therapy for use in cancer. Tamoxifen's use, MOA, toxicities, and drug interactions are also discussed.

en

00:14:43

Ask OncoPharm: Advice for PGY2 Oncology Pharmacy...

OncoPharm ·

2019/06/27

We open up the Ask #OncoPharm inbox to answer a listener question - What advice do you have before starting my PGY2 Oncology Pharmacy Residency?

en

00:15:02

Pembrolizumab Nets 2 More Approvals

OncoPharm ·

2019/06/20

Discussing recent FDA-approvals of pembrolizumab for metastatic or unresectable, recurrent Head & Neck Cancer (1st line) and Small Cell Lung Cancer (3rd line)

en

00:13:29

Polatuzumab-vedotin

OncoPharm ·

2019/06/13

A newly approved drug for relapsed/refractory diffuse large B-cell lymphoma is discussed as well as PBR.

en

00:18:24

ASCO '19

OncoPharm ·

2019/06/06

Concise reviews of 6 studies from ASCO '19. #Oncopharm agents discussed include olaparib, ribociclib, pembrolizumab, dabrafenib/trametinib, and *losartan. *caveats apply

en

00:20:37

Alpelisib

OncoPharm ·

2019/05/30

Discussing the 1st PI3-kinase inhibitor approved for a solid tumor, alpelisib for HR(+), HER2(-) metastatic breast cancer as 2nd line treatment. Worth sharing with her endocrine/DM colleagues...

en

00:13:38

AC - - > T (q 3 week)

OncoPharm ·

2019/05/23

The Landmarks in #OncoPharm continues down its breast cancer-centric track with the landmark CALGB 9344 trial that established the role of paclitaxel in the adjuvant setting --> https://ascopubs.org/doi/pdf/10.1200/JCO.2003.02.063

en

00:14:32

AC (NSABP B-15)

OncoPharm ·

2019/05/23

The Landmarks in #OncoPharm series returns with a discussion of NSABP B-15, which established AC as a standard adjuvant chemo regimen for breast cancer --> (https://ascopubs.org/doi/abs/10.1200/JCO.1990.8.9.1483)

en

00:13:00

May Approvals, More Questions

OncoPharm ·

2019/05/16

Running through updated FDA approvals from this month (ivosidenib, T-DM1, ramucirumab, avelumab/axitinib, & venetoclax/obinutuzumab) and how these approvals raise more questions.

en

00:19:14

Imatinib

OncoPharm ·

2019/05/09

The Foundations of OncoPharm returns with imatinib, the 1st TKI. Discussion includes its history (and how imatinib's Phase I study almost didn't happen), uses, and toxicity.

en

00:14:09

Updates: bb2121 (myeloma CAR-T) and 1st line use of...

OncoPharm ·

2019/05/02

Discussion of 2 important malignant hematology updates: the NEJM publication of the 1st published results of CAR-T therapy in multiple myeloma and the FDA-approval of ivosidenib in frail AML patients (with IDH1 mutations).

en

00:11:52

Lenvatinib vs. Sorafenib (HCC)

OncoPharm ·

2019/04/24

Reviewing the REFLECT (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext) study and its take-home points on selecting an agent for advanced HCC.

en

00:22:06

Erdafitinib

OncoPharm ·

2019/04/18

Summary of erdafitinib's FDA-approval including dosing, MOA, toxicity, and (wait 'til the end) prevalence of FGFR mutations. Ifos. Eye-Phos.

en

00:14:22

HOPA '19 Reflections

OncoPharm ·

2019/04/11

Reflections offered from HOPA's 2019 annual conference on cabozantinib, regorafenib, low-dose azacitidine, SC granisetron (this is a thing), clinical trial hope, and opportunities for students in HOPA

en

00:11:31

OncoPharm M & M - Drug Interaction

OncoPharm ·

2019/04/02

Debut of a new feature: OncoPharm M & M, where we'll discuss notable case reports of #oncopharm misadventures....how they happened...and how we can prevent them in the future. Our first installment in this series discusses a drug interaction between idelalisib & diazepam (Case Report Link: https://doi.org/10.1177%2F1078155216653705).

en

00:17:40

Etoposide

OncoPharm ·

2019/03/28

Our Foundations in #OncoPharm returns with etoposide, including a deeper than necessary discussion of the historical medical(?) uses of podophyllotoxins, its MOA, uses, and toxicities.

en

00:13:45

Updates: Venetoclax use in multiple myeloma,...

OncoPharm ·

2019/03/21

This week brought several notable updates we discuss: the FDA's concern with a venetoclax clinical trial in multiple myeloma patients, atezolizumab's expected FDA-approval for small cell lung cancer, and some neuro-oncology guideline endorsements.

en

00:14:03

Metastatic Pancreatic CAncer

OncoPharm ·

2019/03/14

Brief background on metastatic pancreatic cancer is provided, followed by a brief discussion of the main landmark clinical trials (and one not-so-landmark study) in this difficult disease state.

en

00:14:01

S.C. Monoclonal Antibodies

OncoPharm ·

2019/03/08

Coming to a P & T committee meeting near you....it's subcutaneous (S.C.) monoclonal antibodies. We discuss the two currently FDA-approved formulations: rituximab + hyaluronidase and trastuzumab + hyaluronidase.

en

00:23:46

Lessons Learned (from the last week)

OncoPharm ·

2019/02/28

Providing some clinical pearls learned in the last week regarding patient education for ruxolitinib & alectinib. Then (11:50) we recap follow-up publications from Keynote-24 & the BRIGHT studies, before finishing up the week's journal scan with a discussion of the optimal dose of nivolumab + ipilimumab in melanoma and who may NOT benefit from palbociclib.

en

424 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter